Nephros Inc (NEPH) Stock Price & Analysis
Nephros Inc (NEPH) fell 4.13% to USD 3.25 as of June 10, 2026 at 05:55 UTC, according to Nexqual real-time market data.
NEPH last closed at USD 3.39; the session ranged USD 3.25–3.4 on volume of 13,488 shares. Market capitalization is $35.28M, with a 52-week range of USD 2.66–6.42 (NCM). Source: Nexqual, June 10, 2026 at 05:55 UTC.
Key Statistics (as of June 10, 2026 at 05:55 UTC)
| Price | USD 3.25 |
|---|---|
| Change | ▼ 4.13% (down) |
| Previous Close | USD 3.39 |
| Open | USD 3.36 |
| Day Range | USD 3.25 – 3.4 |
| 52-Week Range | USD 2.66 – 6.42 |
| Volume | 13,488 shares |
| Market Cap | $35.28M |
| Exchange | NCM |
Technical Analysis (NEPH)
Nexqual's technical model rates NEPH "NEUTRAL" based on 2 bullish and 3 bearish signals across 123 daily candles, as of June 10, 2026 at 05:55 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.99 (neutral) |
| vs SMA50 | Above (USD 3.21) |
| MACD | 0.09 (positive) |
Analyst Ratings (NEPH)
Wall Street analysts rate NEPH "None" based on 2 analysts, with a mean price target of USD 7 (range USD 6–8), per Nexqual as of June 10, 2026 at 05:55 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 7 |
| High Target | USD 8 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (NEPH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0 |
| Revenue Estimate | $5.05M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.01 vs est 0.01 ▲ beat |
| 2025-12-31 | USD 0.01 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.03 vs est -0.02 ▲ beat |
| 2025-06-30 | USD 0.02 vs est -0.03 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:55 UTC.
Financials & Fundamentals (NEPH)
| Total Revenue | $19.12M |
|---|---|
| Revenue Growth (YoY) | +6.90% |
| Gross Margin | +59.95% |
| Operating Margin | +1.86% |
| Profit Margin | +4.06% |
| ROE | +7.76% |
| Debt / Equity | 9.05 |
| Current Ratio | 4.55 |
| Total Cash | $4.02M |
| Total Debt | $968,000 |
| Free Cash Flow | $-773,500 |
Source: Nexqual, June 10, 2026 at 05:55 UTC.
Financial Health Score (NEPH)
Nexqual rates Nephros Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:55 UTC.
| Growth | Strong — Revenue +33% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$774K, burning cash |
| Efficiency | Mixed — ROE 8%, ROA 3.3% |
Ownership (NEPH)
| Insider Ownership | +12.84% |
|---|---|
| Institutional Ownership | +49.48% |
| Shares Outstanding | 10.86M |
| Float | 8.83M |
| Short % of Float | +0.38% |
Source: Nexqual, June 10, 2026 at 05:55 UTC.
Leadership (NEPH)
Nephros Inc is led by Robert Banks (age 50), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:55 UTC.
| President, CEO & Director | Robert Banks (age 50) |
|---|---|
| Chief Financial Officer | Judy F. Krandel C.F.A. (age 60) |
| Director of Brand, Marketing & Business Development | Brianne McGuire |
| Vice President of Quality, Regulatory, & Human Resources | Vashone R. Thomas |
| President of Aether Water Systems | Greg Lucas |
Major Backers & Investors (NEPH)
Notable institutional backers of Nephros Inc include Wexford Capital LP, Topline Capital Management, LLC, Cornerstone Capital, Inc., according to Nexqual as of June 10, 2026 at 05:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wexford Capital LP | 46.93% |
| Topline Capital Management, LLC | 7.58% |
| Cornerstone Capital, Inc. | 1.68% |
| Bard Associates Inc. | 1.58% |
| Mesirow Financial Investment Management, Inc. | 1.56% |
| Morgan Stanley | 1.45% |
| Renaissance Technologies | 1.3% |
| HighTower Advisors, LLC | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.18% |
| Geode Capital | 0.95% |
Source: Nexqual, June 10, 2026 at 05:55 UTC.
From Nephros Inc's Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- If the FDA believes that we or any of our contract manufacturers, or regulated suppliers, are not in compliance with these requirements, there may be a material adverse effect on our manufacturing operations, affecting our ability to sell.   Regulatory Authorities in Regions Outside of the United States   We have obtained regulatory approvals to market certain medical filtration products outside of the United States, including in Canada and Brazil.
- Our methods of competition in the water filtration domain include:     Intellectual Property   Patents   We protect our technology and products through patents and patent applications.
Partnerships
- Under the License and Supply Agreement, as amended, Medica granted us an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the filtration products worldwide, with certain limitations on territory, during the term of the License and Supply Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XGN | Exagen Inc. | USD 4.31 | ▲ 0.47% |
| APYX | Apyx Medical Corporation | USD 4.86 | ▲ 8.72% |
| KRMD | KORU Medical Systems, Inc. | USD 4 | ▲ 1.78% |
| CTSO | Cytosorbents Corporation | USD 0.42 | ▼ 7.95% |
| PDEX | Pro-Dex, Inc. | USD 65 | ▼ 0.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:55 UTC. This page is informational and not investment advice.